News & Events about Glaukos Corp.
Shares of Glaukos Co. (NYSE:GKOS Get Rating) have been given a consensus rating of Hold by the eleven ratings firms that are presently covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, four have given a hold recommendation and five have ...
Shares of Glaukos Co. (NYSE:GKOS Get Rating) have been assigned an average recommendation of Hold from the eleven analysts that are currently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, four have given a hold ...
Shares of Glaukos Co. (NYSE:GKOS Get Rating) have received an average rating of Hold from the eleven ratings firms that are covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and five ...
Glaukos Co. (NYSE:GKOS Get Rating) has been given an average rating of Hold by the eleven ratings firms that are presently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and five have...
Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release first quarter 2023 financial results after the market close on Wednesday, May 3, 2023. The...